Company news

Abbisko Cayman Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 2, 2026

Change of company name

November 1, 2026

Next Day Disclosure Returns

October 30, 2026

Next Day Disclosure Returns

October 29, 2026

Next Day Disclosure Returns

October 27, 2026

Next Day Disclosure Returns

October 23, 2026

Next Day Disclosure Returns

October 21, 2026

Voluntary announcement - abbisko therapeutics' lavengratinib (ABSK061) for the treatment of achondroplasia granted orphan designation by ema

October 20, 2026

Next Day Disclosure Returns

October 20, 2026

Next Day Disclosure Returns

October 15, 2026

Next Day Disclosure Returns

October 14, 2026

Next Day Disclosure Returns

October 8, 2026

Next Day Disclosure Returns

October 7, 2026

Next Day Disclosure Returns

October 6, 2026

Next Day Disclosure Returns

October 5, 2026

Next Day Disclosure Returns

October 2, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 2, 2026

Next Day Disclosure Returns

September 29, 2026

Next Day Disclosure Returns

September 28, 2026

2026 Interim report

September 22, 2026

Voluntary announcement - abbisko therapeutics announces positive preliminary phase II results with lavengratinib (ABSK061) for the treatment of achondroplasia

September 20, 2026

Poll results of the extraordinary general meeting held on September 17, 2026

September 17, 2026

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

April 22, 2026

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

January 12, 2026

Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor

December 22, 2025

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

June 15, 2025

Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT

June 10, 2025

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

May 26, 2025

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress

May 12, 2025

2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1

April 27, 2025

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

March 31, 2025

Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）

January 8, 2024

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

December 4, 2023

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

July 4, 2022

Abbisko Cayman: Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx

October 14, 2021

Decks

The 5 newest of 7 decks. Every deck is listed under its year.